IRWD Stock Rises as Q2 Earnings & Revenues Trump Estimates
Ironwood shares jump 9.3% as second-quarter earnings and revenues top estimates. The company maintains its 2025 outlook.
Ironwood ( IRWD ) Q2 EPS Jumps 600%
Ironwood Pharmaceuticals ( NASDAQ:IRWD ) , a specialty pharmaceutical company known for developing therapies for gastrointestinal conditions, delivered financial results on August 7, 2025, for its second quarter. The company beat analyst expectations on both non-GAAP earnings and GAAP revenue.
Ironwood Pharmaceuticals ( IRWD ) Beats Q2 Earnings and Revenue Estimates
Ironwood (IRWD) delivered earnings and revenue surprises of +800.00% and +37.83%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update
WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver manifestations of AATD, rapidly advancing in RestorAATion-2 study of AATD patients. multi-dosing is complete in first cohort ( 200 mg ) and single dosing is complete in second ...
Why Is Ironwood ( IRWD ) Down 18.4% Since Last Earnings Report?
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates
Ironwood incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year. Shares fall.
Ironwood Pharmaceuticals ( IRWD ) Reports Q1 Loss, Misses Revenue Estimates
Ironwood (IRWD) delivered earnings and revenue surprises of -180% and 21.83%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Vivos Therapeutics, Inc. ( VVOS ) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Vivos Therapeutics (VVOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Recursion Pharmaceuticals ( RXRX ) Reports Q1 Loss, Misses Revenue Estimates
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -13.64% and 26.82%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Ironwood Pharmaceuticals ( IRWD ) to Report a Decline in Earnings: What to Look Out for
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News
BMY and VERV are in the spotlight this week following the failure of a late-stage study and positive cholesterol study data, respectively.
Ironwood Shares Tank on Regulatory Update for Apraglutide
Per the latest discussion with the FDA, a confirmatory phase III study is required to seek approval for IRWD's apraglutide in short bowel syndrome with intestinal failure.
This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - General Motors ( NYSE:GM ) , HCA Healthcare ( NYSE:HCA )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug - Ironwood Pharmaceuticals ( NASDAQ:IRWD )
27 apraglutide-treated patients achieved enteral autonomy in the long-term extension trial. NDA submission for apraglutide expected to be completed by Q3 2025. China's new tariffs just reignited the same market patterns that led to triple- and quadruple-digit wins for Matt Maley.
Crude Oil Moves Lower; M&T Bank Earnings Miss Views - Ironwood Pharmaceuticals ( NASDAQ:IRWD ) , MarineMax ( NYSE:HZO )
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 150 points on Monday. The Dow traded up 0.43% to 40,384.20 while the NASDAQ gained 0.33% to 16,778.86. The S&P 500 also rose, gaining, 0.55% to 5,392.71. Information technology shares surged by 2% on ...
Nasdaq Surges 2%; Goldman Sachs Posts Upbeat Earnings - Ironwood Pharmaceuticals ( NASDAQ:IRWD ) , Goldman Sachs Group ( NYSE:GS )
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 2% on Monday. The Dow traded up 0.99% to 40,610.00 while the NASDAQ gained 2.02% to 17,062.41. The S&P 500 also rose, gaining, 1.48% to 5,442.94. Information technology shares surged by 2.2% on Monday.
Corcept ( CORT ) Stock Jumps 109.1%: Will It Continue to Soar?
Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Catalyst ( CPRX ) Surges 6.2%: Is This an Indication of Further Gains?
Catalyst (CPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
IRWD's Q4 Earnings and Revenues Fall Shy of Estimates, Stock Down
Ironwood reports weaker-than-expected results for the fourth quarter of 2024. The company maintains total revenue guidance for 2025.
Ironwood Pharmaceuticals ( IRWD ) Q4 Earnings and Revenues Miss Estimates
Ironwood (IRWD) delivered earnings and revenue surprises of -80% and 1.56%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
IRWD Begins Apraglutide NDA Submission, Announces Job Cuts, Stock Falls
Ironwood begins the rolling NDA filing for apraglutide to treat short bowel syndrome patients dependent on parenteral support.
Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications
The talks around drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices that go into effect in 2027.
Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up
BEAM appoints Sravan K. Emany as its new chief financial officer, effective Dec. 19. Shares rise on this leadership transition.
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer
CAMBRIDGE, Mass., Dec. 06, 2024 ( GLOBE NEWSWIRE ) -- Beam Therapeutics Inc. ( Nasdaq: BEAM ) , a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer ( CFO ) , effective December 19, 2024.
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer - Beam Therapeutics ( NASDAQ:BEAM ) , Assertio Holdings ( NASDAQ:ASRT )
CAMBRIDGE, Mass., Dec. 06, 2024 ( GLOBE NEWSWIRE ) -- Beam Therapeutics Inc. BEAM, a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer ( CFO ) , effective December 19, 2024.
Ironwood's Q3 Earnings Lag Estimates, Revenues Top, Stock Down
IRWD's third-quarter earnings miss estimates while revenues beat the same. The company maintains revenue guidance for 2024. Stock falls.
Ironwood Pharmaceuticals ( IRWD ) Misses Q3 Earnings Estimates
Ironwood (IRWD) delivered earnings and revenue surprises of -77.78% and 2.94%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Op-ed: Here's why a sale of Bausch + Lomb could lead to a windfall for Bausch Health investors
Hedge fund managers sit on the boards of Bausch Health and Bausch + Lomb. They don't think like your typical corporate board, writes Ken Squire of 13D Monitor.
Implied Volatility Surging for Ironwood ( IRWD ) Stock Options
Investors need to pay close attention to Ironwood (IRWD) stock based on the movements in the options market lately.
Ironwood Q2 Earnings & Revenues Fall Shy of Estimates - AstraZeneca ( NASDAQ:AZN ) , AbbVie ( NYSE:ABBV )
Ironwood Pharmaceuticals, Inc. IRWD reported break-even earnings for the second quarter of 2024 compared with the Zacks Consensus Estimate of earnings of 17 cents per share. The company had recorded adjusted earnings of 31 cents per share in the year-ago quarter.
Ironwood ( IRWD ) Q2 Earnings & Revenues Fall Shy of Estimates
Ironwood (IRWD) reports breakeven earnings for second-quarter 2024. Revenues miss estimates. The company lowers revenue guidance for 2024. Stock falls.
Ironwood Pharmaceuticals ( IRWD ) Reports Break-Even Earnings for Q2
Ironwood (IRWD) delivered earnings and revenue surprises of -100% and 9.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics ( HRTX ) Reports Q2 Loss, Tops Revenue Estimates
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -50% and 1.91%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Ironwood Pharmaceuticals ( IRWD ) Q2 Earnings Expected to Decline
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for July 23rd
ALK, DINO and IRWD have been added to the Zacks Rank #5 (Strong Sell) List on July 23, 2024.
Implied Volatility Surging for Ironwood Pharmaceuticals ( IRWD ) Stock Options
Investors need to pay close attention to Ironwood Pharmaceuticals (IRWD) stock based on the movements in the options market lately.
Ironwood Pharmaceuticals ( NASDAQ:IRWD ) Upgraded at StockNews.com
Ironwood Pharmaceuticals ( NASDAQ:IRWD - Get Free Report ) was upgraded by equities researchers at StockNews.com from a "hold" rating to a "buy" rating in a research report issued on Tuesday.
Ironwood Pharmaceuticals ( NASDAQ:IRWD ) Downgraded by StockNews.com to "Hold"
StockNews.com cut shares of Ironwood Pharmaceuticals ( NASDAQ:IRWD - Free Report ) from a buy rating to a hold rating in a research note published on Monday morning.
New Strong Sell Stocks for July 5th
ARCO, IRWD and AVT have been added to the Zacks Rank #5 (Strong Sell) List on July 5, 2024.
COUR Pharmaceuticals Appoints Tim Walbert to its Board of Directors
CHICAGO, June 26, 2024 ( GLOBE NEWSWIRE ) -- COUR Pharmaceuticals, a clinical-stage biotechnology company focused on the development of first-in-class, disease-modifying therapies designed to induce antigen-specific tolerance for immune-mediated diseases, today announced the appointment of Tim ...
Asana, Clover Health Investments, Hertz Global And Other Big Stocks Moving Higher On Friday - Asana ( NYSE:ASAN )
U.S. stocks were mixed, with the Dow Jones index gaining around 50 points on Friday. Shares of Asana, Inc. ASAN rose sharply during Friday's session after the company announced a $150 million share repurchase program and reaffirmed its forward guidance.
Ironwood Pharmaceuticals ( NASDAQ:IRWD ) Upgraded to Buy at StockNews.com
StockNews.com upgraded shares of Ironwood Pharmaceuticals ( NASDAQ:IRWD - Free Report ) from a hold rating to a buy rating in a research report released on Tuesday.
Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer
BOSTON and LONDON, June 10, 2024 ( GLOBE NEWSWIRE ) -- Centessa Pharmaceuticals plc ( Nasdaq: CNTA ) , a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that John Crowley CPA, has been appointed Chief ...
Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer - Centessa Pharmaceuticals ( NASDAQ:CNTA )
BOSTON and LONDON, June 10, 2024 ( GLOBE NEWSWIRE ) -- Centessa Pharmaceuticals plc CNTA, a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that John Crowley CPA, has been appointed Chief Financial Officer, ...
Ironwood ( IRWD ) Q1 Earnings & Revenues Fall Shy of Estimates
Ironwood (IRWD) incurs loss in the first quarter of 2024. Revenues decline year over year and miss estimates. The company lowers revenue guidance for 2024. Stock falls.
Earnings Preview: Ironwood Pharmaceuticals ( IRWD ) Q1 Earnings Expected to Decline
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
George Medicines Appoints Mark Mallon as Chief Executive Officer and Board Director
London, UK 29 April 2024 - George Medicines, a late-stage, biopharmaceutical company addressing significant unmet need in the treatment of cardiometabolic disease, announces the appointment of Mark Mallon as its new Chief Executive Officer and Board Director, effective immediately.
SAP's Q1 Earnings and Revenues Rise Y/Y on Cloud Strength
SAP's first-quarter performance benefits from continued strength in its cloud business, especially its Cloud ERP suite.
SAP Announces Q1 2024 Results
• Cloud revenue up 24% and up 25% at constant currencies, supported by 32% Cloud ERP Suite revenue growth at constant currencies • Current cloud backlog of €14.2 billion, up 27% and up 28% at constant currencies • IFRS cloud gross profit up 27%, non-IFRS cloud gross profit up 27% and up 28% at ...
Ironwood Pharmaceuticals ( NASDAQ:IRWD ) Downgraded by StockNews.com
Ironwood Pharmaceuticals ( NASDAQ:IRWD - Get Free Report ) was downgraded by equities research analysts at StockNews.com from a "buy" rating to a "hold" rating in a research note issued to investors on Saturday. Other equities analysts have also recently issued research reports about the stock.
